Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases

International Journal of Colorectal Disease

Volumn 27, Issue 5, 2012, Pages 635-645

  Neeff, Hannes P ^a   Drognitz, Oliver ^a   Klock, Andrea ^a   Illerhaus, Gerald ^a   Opitz, Oliver G ^a   Hopt, Ulrich T ^a   Makowiec, Frank ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Chemotherapy; Colorectal cancer; Complications; Liver metastasis; Surgery

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ABDOMINAL ABSCESS; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; LAPAROTOMY; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; REOPERATION; SURGICAL INFECTION; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84862976352     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-011-1360-z     Document Type: Article

References (57)

1. Boyle P, Leon ME (2002) Epidemiology of colorectal cancer. Br Med Bull 64:1-25
2. Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22:191-197. doi:10.1055/s-0029-1242458
3. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P, European Colorectal Metastases Treatment Group (2006) Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212-2221. doi:10.1016/j.ejca.2006.04.012
4. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309-318
5. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818-825
6. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. AnnSurg 241:715-22, discussion
7. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, Taylor BR, Langer B, Gallinger S, Wei AC (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202:468-475
8. Neeff H, Hörth W, Makowiec F, Fischer E, Imdahl A, Hopt UT, Passlick B (2009) Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. J Gastrointest Surg 13:1813-1820. doi:10.1007/s11605-009- 0960-1
9. Adam R (2003) Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14(2): ii13-ii16
10. Pawlik TM, Schulick RD, Choti MA (2008) Expanding criteria for resectability of colorectal liver metastases. Oncologist 13:51-64. doi:10.1634/theoncologist.2007-0142
11. Rivoire M, De Cian F, Meeus P, Négrier S, Sebban H, Kaemmerlen P (2002) Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95:2283-2292. doi:10.1002/cncr.10973
12. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-57, discussion 657-8
13. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875. doi:10.1200/JCO.2005.07.113
14. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676. doi:10.1200/JCO.2006.09.0928
15. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-20, discussion 520-2
16. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOL-FOXIRI) followed by radical surgery of metastases. Ann Surg 249:420-425. doi:10.1097/SLA.0b013e31819a0486
17. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, Ijzermans J, Hubert C et al (2010) Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252:774-787. doi:10.1097/SLA.0b013e3181fcf3e3
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. doi:10.1056/NEJMoa032691
19. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048. doi:10.1056/NEJMoa071834
20. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765. doi:10.1056/ NEJMoa0804385
21. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460-466
22. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072. doi:10.1200/JCO.2005.05.3074
23. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860-868. doi:10.1007/s11605-007-0149-4
24. Makowiec F, Möhrle S, Neeff H, Drognitz O, Illerhaus G, Opitz OG, Hopt UT, zur Hausen A (2011) Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg 15(11):153-64. doi:10.1007/s11605-010-1368-7
25. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795. doi:10.1038/sj.bjc.6603813
26. Tarnawski AS, Jones MK (1998) The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduc-tion pathways. J Clin Gastroenterol 27(Suppl 1):S12-S20
27. Ito H, Are C, Gonen M, D'Angelica M, Dematteo RP, Kemeny NE, Fong Y, Blumgart LH, Jarnagin WR (2008) Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 247:994-1002. doi:10.1097/SLA.0b013e31816c405f
28. Schepers A, Mieog S, van de Burg BB, van Schaik J, Liefers GJ, Marang-van de Mheen PJ (2010) Impact of complications after surgery for colorectal liver metastasis on patient survival. J Surg Res 164:e91-e97. doi:10.1016/j.jss.2010. 07.022
29. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 236:397-406. doi:10.1097/01.SLA.0000029003.66466.B3
30. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O (2000) Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191:38-46
31. Cescon M, Vetrone G, Grazi GL, Ramacciato G, Ercolani G, Ravaioli M, Del Gaudio M, Pinna AD (2009) Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg 249:995-1002. doi:10.1097/SLA.0b013e3181a63c74
32. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572. doi:10.1056/NEJMoa0808268
33. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845-853. doi:10.1016/j.jamcollsurg.2005.01.024
34. Fong Y, Bentrem DJ (2006) CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 243:8-9
35. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, Jarnagin WR (2003) Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7:1034-1044
36. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunvén P, Yamazaki S, Hasegawa H, Ozaki H (1990) Preoper-ative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107:521-527
37. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H (2000) Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 232:777-785
38. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173-180. doi:10.1002/jso.20301
39. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB (2007) Lack of evidence for increased operative morbidity after hepatec-tomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14:759-765. doi:10.1245/s10434-006- 9074-0
40. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254-5260. doi:10.1200/JCO.2008.17.7857
41. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, Clary BM (2008) Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96-106. doi:10.1016/j.jamcollsurg.2007.06. 290
42. Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T (2010) Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevaci-zumab: a case-controlled study. Ann Surg 252:124-130. doi:10.1097/SLA.0b013e3181deb67f
43. Pessaux P, Panaro F, Casnedi S, Zeca I, Marzano E, Bachellier P, Jaeck D, Chenard MP (2010) Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepato-toxicity: preliminary results of a case-control study. Eur J Surg Oncol 36:575-582. doi:10.1016/j.ejso.2010.04.010
44. Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, Mittal V, Kobayashi H et al (2010) Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468:310-315. doi:10.1038/nature09493
45. van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malagó M, Jalan R, Saner FH (2008) Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 28:767-780. doi:10.1111/j.1478-3231.2008.01777.x
46. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850
47. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1-7
48. Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16:1553-1559. doi:10.1245/s10434-009-0447-z
49. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN (2008) Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15:2765-2772. doi:10.1245/s10434-008-0035-7
50. Peeters M, Price T, Van Laethem JL (2009) Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 14:29-39. doi:10.1634/theoncologist.2008-0167
51. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M et al (2004) Cetuximab mono-therapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345. doi:10.1056/NEJMoa033025
52. Van Cutsem E (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11:1010-1017. doi:10.1634/theoncologist.11-9-1010
53. Fakih M, Vincent M (2010) Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 17(Suppl 1):S18-S30
54. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343:905-914. doi:10.1056/NEJM200009283431302
55. Nagino M, Kanai M, Morioka A, Yamamoto H, Kawabata Y, Hayakawa N, Nimura Y (2000) Portal and arterial embolization before extensive liver resection in patients with markedly poor functional reserve. J Vasc Interv Radiol 11:1063-1068
56. Gruttadauria S, Luca A, Mandala' L, Miraglia R, Gridelli B (2006) Sequential preoperative ipsilateral portal and arterial embolization in patients with colorectal liver metastases. World J Surg 30:576-578. doi:10.1007/s00268- 005-0423-0
57. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F et al (2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11:845-852. doi:10.1016/S1470-2045(10) 70175-3